HARARE, May 17 (NewsDay Live) — Zimbabwe’s Competition and Tariff Commission (CTC) has approved the proposed acquisition of an 88.1% stake in Vertice Medtech Holdings Proprietary Limited by Vertice Bidco Proprietary Limited, a special purpose vehicle created by France-headquartered private equity firm Amethis Fund III.
The merger, classified as a conglomerate transaction, was approved without conditions, according to the CTC’s Q1 2026 merger decisions report.
The deal gives Amethis indirect control of Vertice Medtech Holdings, a specialised medical technology distributor and manufacturer supplying blood transfusion technologies, mobile clinics and pacemakers to the Zimbabwean market through distributors.
CTC said Vertice Bidco was established solely for the acquisition by Amethis, an equity fund with operations in South Africa and interests in healthcare businesses across the continent.
Amethis already has a footprint in Zimbabwe through investments linked to pharmaceutical and medical supply businesses under the Avacare group.
The commission said Avacare operates locally through subsidiaries including New Avakash, a pharmaceutical and healthcare solutions company; STM, a distributor of pharmaceuticals, medical consumables and hospital equipment; and Devices & Disposables, a supplier of medical devices and consumables.
Although Vertice Medtech Holdings has no physical presence in Zimbabwe, the company derives revenue from the sale of medical technologies and equipment in the country.
CTC identified the relevant market as the supply of pharmaceuticals, medical devices, consumables and equipment, including blood transfusion technologies, mobile clinics and pacemakers in Zimbabwe.
- Mavhunga puts DeMbare into Chibuku quarterfinals
- Bulls to charge into Zimbabwe gold stocks
- Ndiraya concerned as goals dry up
- Letters: How solar power is transforming African farms
Keep Reading
The commission said the transaction raised no competition concerns and cleared the merger unconditionally.
